Secretory leukocyte protease inhibitor and risk of heart failure in the Multi-Ethnic Study of Atherosclerosis

[1]  M. Naser‐Moghadasi,et al.  An innovative antenna array with high inter element isolation for sub-6 GHz 5G MIMO communication systems , 2022, Scientific Reports.

[2]  Mohammad M. Fakharian,et al.  A high gain multiband offset MIMO antenna based on a planar log-periodic array for Ku/K-band applications , 2022, Scientific Reports.

[3]  Bjarni V. Halldórsson,et al.  Large-scale integration of the plasma proteome with genetics and disease , 2021, Nature Genetics.

[4]  J. Pankow,et al.  Adhesion pathway proteins and risk of atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis , 2021, BMC Cardiovascular Disorders.

[5]  R. Abd‐Alhameed,et al.  Optimum power transfer in RF front end systems using adaptive impedance matching technique , 2021, Scientific Reports.

[6]  N. Soin,et al.  High-isolation antenna array using SIW and realized with a graphene layer for sub-terahertz wireless applications , 2021, Scientific Reports.

[7]  R. Abd‐Alhameed,et al.  Bandwidth and gain enhancement of composite right left handed metamaterial transmission line planar antenna employing a non foster impedance matching circuit board , 2021, Scientific Reports.

[8]  C. Watson,et al.  Biomarker profiling for risk of future heart failure (HFpEF) development , 2021, Journal of translational medicine.

[9]  Sanjiv J. Shah,et al.  Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction , 2020, Circulation.

[10]  Di Zhao,et al.  Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction , 2020, Circulation. Heart failure.

[11]  Zhuyin Li,et al.  Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. , 2020, Journal of the American College of Cardiology.

[12]  S. Heymans,et al.  Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding , 2020, Cells.

[13]  G. Gordon,et al.  Biomarkers in Heart Failure With Preserved Ejection Fraction: An Update on Progress and Future Challenges. , 2020, Heart, lung & circulation.

[14]  S. Kumphune,et al.  Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor (rhSLPI) reduces an in vitro ischemia/reperfusion injury in rat cardiac myoblast (H9c2) cell , 2018, Biomolecular concepts.

[15]  Sanjiv J. Shah,et al.  Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction , 2018, JAMA cardiology.

[16]  D. Jacobs,et al.  Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi‐Ethnic Study of Atherosclerosis) , 2018, Journal of the American Heart Association.

[17]  J. Pankow,et al.  Elevated Levels of Adhesion Proteins Are Associated With Low Ankle–Brachial Index , 2017, Angiology.

[18]  P. Bakke,et al.  Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease , 2017, European Respiratory Journal.

[19]  Christian Gieger,et al.  Connecting genetic risk to disease end points through the human blood plasma proteome , 2016, Nature Communications.

[20]  K. Murzyn,et al.  Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response. , 2016, Cytokine & growth factor reviews.

[21]  J. Pankow,et al.  Impact of adiposity on cellular adhesion: The Multi‐Ethnic Study of atherosclerosis (MESA) , 2016, Obesity.

[22]  Y. Hua,et al.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications. , 2015, Biochimica et biophysica acta.

[23]  I. Jaspers,et al.  Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[24]  T. Midoro-Horiuti,et al.  Estrogen effects in allergy and asthma , 2013, Current opinion in allergy and clinical immunology.

[25]  D. Bluemke,et al.  Cardiovascular Imaging for Assessing Cardiovascular Risk in Asymptomatic Men Versus Women: The Multi-Ethnic Study of Atherosclerosis (MESA) , 2011, Circulation. Cardiovascular imaging.

[26]  E. Werner,et al.  The Effect of Secretory Leukocyte Protease Inhibitor (SLPI) on Ischemia/Reperfusion Injury in Cardiac Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[28]  A. Ding,et al.  Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI , 2007, Nature Immunology.

[29]  N. Reichek.  The Multi-Ethnic Study of Atherosclerosis (MESA) and myocardial function: where is the boundary between risk factor and disease? , 2006, Journal of the American College of Cardiology.

[30]  S. Doumas,et al.  Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor , 2005, Infection and Immunity.

[31]  Paul M. Ridker,et al.  Inflammation as a Cardiovascular Risk Factor , 2004, Circulation.

[32]  T. Isono,et al.  Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure , 2003, Circulation.

[33]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[34]  A. Kulkarni,et al.  Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing , 2000, Nature Medicine.

[35]  S. Wahl,et al.  Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. , 1997, The Journal of clinical investigation.

[36]  D. Radzioch,et al.  Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial Lipopolysaccharide , 1997, Cell.

[37]  A. Shenkin,et al.  C‐reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis , 1989, The British journal of surgery.

[38]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[39]  松本 武洋.  Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure , 2003 .

[40]  J. Schalkwijk,et al.  Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[41]  A. Lentsch,et al.  Inhibition of NF-κB Activation and Augmentation of IκBβ by Secretory Leukocyte Protease Inhibitor during Lung Inflammation , 1999 .

[42]  A. Lentsch,et al.  Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. , 1999, The American journal of pathology.